Comparison of the Clinical Efficacy of Abobotulinumtoxin A (ABO) and Onabotulinumtoxin A (ONA) in the Treatment of Crow’s Feet Wrinkles: A Split-Face Study

Abstract

ABSTRACTPurpose: Comparing the clinical efficacy of Abobotulinumtoxin A (ABO) and Onabotulinumtoxin A(ONA) using a dosing ratio of 2.5U:1.0U in the treatment of crow’s feet wrinkles. Subjects and methods: A single-blinded, randomized, split-face study, included 40 subjects, with moderate-to-severe crow’s feet wrinkles. Patients were subjected to a dose equivalence of (ABO):(ONA); 2.5:1.0 U. Post treatment evaluation was done on 7, 30, and 120 days, comparing: Time, Duration, and Degree of Improvement; Patients Satisfaction. Results: No significant difference was found between ABO & ONA regarding duration and time to improvement on static posture. While on dynamic posture, ABO showed significantly less time and longer duration. Both products produced highly significant improvement of the wrinkles’ severity on both static and dynamic posture in comparison to the baseline severity. Satisfaction was more with ABO. Conclusion: ABO is a safe, effective alternative to ONA in treating crow’s feet wrinkles.